Tag Archives: NASDAQ:ARWR

The CFO of Arrowhead Pharmaceuticals (NASDAQ: ARWR) is Selling Shares

Yesterday, the CFO of Arrowhead Pharmaceuticals (ARWR – Research Report), Kenneth Allen Myszkowski, sold shares of ARWR for $1.06M. Following Kenneth Allen Myszkowski’s last ARWR Sell transaction on February 27, 2020, the stock climbed by 44.1%. In addition to Kenneth

A Director at Arrowhead Pharmaceuticals (NASDAQ: ARWR) is Selling Shares

Yesterday, a Director at Arrowhead Pharmaceuticals (ARWR – Research Report), Mauro Ferrari, sold shares of ARWR for $480K. Following Mauro Ferrari’s last ARWR Sell transaction on June 28, 2019, the stock climbed by 19.9%. See today’s analyst top recommended stocks

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arrowhead Pharmaceuticals (NASDAQ: ARWR), Selecta Biosciences (NASDAQ: SELB) and Alkermes (NASDAQ: ALKS)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Arrowhead Pharmaceuticals (ARWR – Research Report), Selecta Biosciences (SELB – Research Report) and Alkermes (ALKS – Research Report). Arrowhead Pharmaceuticals (ARWR) H.C. Wainwright

A Director at Arrowhead Pharmaceuticals is Exercising Options

Yesterday it was reported that a Director at Arrowhead Pharmaceuticals (ARWR – Research Report), Michael S. Perry, exercised options to buy 77,000 ARWR shares at $3.70 a share, for a total transaction value of $285.2K. Following Michael S. Perry’s last

Cantor Fitzgerald Remains a Buy on Arrowhead Pharmaceuticals (ARWR)

Cantor Fitzgerald analyst Alethia Young reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) today and set a price target of $58.00. The company’s shares closed last Thursday at $35.13. According to TipRanks.com, Young is a 5-star analyst

B.Riley FBR Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)

In a report issued on March 13, Mayank Mamtani from B.Riley FBR maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a price target of $57.00. The company’s shares closed last Monday at $26.32, close to its